FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a polypeptide for specific binding to IL-13 and TSLP, which contains or consists of five single variable immunoglobulin domains (ISVD), wherein two ISVDs bind to IL-13 and two ISVDs bind to TSLP. Also disclosed is a nucleic acid for expressing a polypeptide, a composition for treating type 2 inflammatory disease, preferably, where type 2 inflammatory disease is selected from asthma and atopic dermatitis. Invention also relates to use of the polypeptide or composition for treating type 2 inflammatory disease.
EFFECT: invention provides obtaining a new type of drug for treating a subject suffering an inflammatory disease.
15 cl, 14 dwg, 37 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES BINDING TO ADAMTS5, MMP13, AND AGGRECAN | 2018 |
|
RU2786659C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
| MMP13-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2784069C2 |
| IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
